We observed strong trends toward decreased sleep percentages in both AD-tau–injected and non–AD-tau–injected APPPS1:E4 mice after the SD time (1400–1700 hours) after 8 weeks of SD treatment compared with the first week of SD. The gene discussed is MAPT; the disease is Alzheimer disease.